Publicaciones en las que colabora con Javier Martínez Sanz (44)

2024

  1. (, 10.2139/ssrn.4579870)

    Frontiers in Immunology

  2. Acceptability of Long-Acting Injectable Antiretroviral Treatment for HIV Management: Perspectives of Patients and Physicians in Spain

    AIDS Patient Care and STDs, Vol. 38, Núm. 7, pp. 305-314

  3. CD4/CD8 ratio and CD8+ T-cell count as prognostic markers for non-AIDS mortality in people living with HIV. A systematic review and meta-analysis

    Frontiers in Immunology, Vol. 15

  4. Design and Proof of Concept of a Web-Based Questionnaire to Identify Patients at Risk for HIV and HCV Infection

    Biomedicines, Vol. 12, Núm. 8

  5. Proteomic snapshot of saliva samples predicts new pathways implicated in SARS-CoV-2 pathogenesis

    Clinical Proteomics, Vol. 21, Núm. 1

  6. Should we measure quality of life among people with HIV? A multicentre survey of physicians' opinions in Spain

    HIV Medicine

  7. Transition times across the HIV care continuum in Spain from 2005 to 2022: a longitudinal cohort study

    The Lancet HIV, Vol. 11, Núm. 7, pp. e470-e478

2023

  1. A gut microbiome signature for HIV and metabolic dysfunction-associated steatotic liver disease

    Frontiers in Immunology, Vol. 14

  2. Author Correction: Differential abundance of lipids and metabolites related to SARS-CoV-2 infection and susceptibility (Scientific Reports, (2023), 13, 1, (15124), 10.1038/s41598-023-40999-5)

    Scientific Reports

  3. CD4/CD8 Ratio During Human Immunodeficiency Virus Treatment: Time for Routine Monitoring?

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Vol. 76, Núm. 9, pp. 1688-1696

  4. Differential abundance of lipids and metabolites related to SARS-CoV-2 infection and susceptibility

    Scientific Reports, Vol. 13, Núm. 1

  5. Expanding HIV clinical monitoring: the role of CD4, CD8, and CD4/CD8 ratio in predicting non-AIDS events

    EBioMedicine, Vol. 95, pp. 104773

  6. From Innovation to Implementation: The Evolution of HIV Pre-Exposure Prophylaxis and Future Implications

    Pathogens, Vol. 12, Núm. 7

  7. Global DNA methylation and telomere length as markers of accelerated aging in people living with HIV and non-alcoholic fatty liver disease

    BMC Genomics, Vol. 24, Núm. 1

  8. HIV and HCV screening by non-infectious diseases physicians: can we improve testing and hidden infection rates?

    Frontiers in Public Health, Vol. 11

  9. Impact of COVID-19 on the Care of Patients with HIV Infection

    Journal of Clinical Medicine, Vol. 12, Núm. 12

  10. Metabolic-Related Outcomes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Adults With Human Immunodeficiency Virus (HIV): A Multicenter Prospective Cohort Study

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Vol. 76, Núm. 3, pp. e652-e660

  11. Prevalence, characteristics, and associated risk factors of drug consumption and chemsex use among individuals attending an STI clinic (EpITs STUDY)

    Frontiers in Public Health, Vol. 11

2022

  1. An Easy-to-Implement Risk Score for Targeted Hepatitis C Virus Testing in the General Population

    Microbiology spectrum, Vol. 10, Núm. 2, pp. e0228621

  2. Differences in saliva ACE2 activity among infected and non-infected adult and pediatric population exposed to SARS-CoV-2

    Journal of Infection, Vol. 85, Núm. 1, pp. 86-89